In Taiwan, drugs for rare diseases are registered through accelerated pathways offered by the TFDA. These orphan drugs benefit from priority review to expedite approval, addressing unmet medical needs. Applicants must submit clinical data, GMP compliance documents, and risk management plans. Post-market monitoring is also required to ensure ongoing safety and efficacy.
